Bayer's Berenberg Target Jumps to EUR 62 as Analyst Backs Pharma Arm Over Consensus
Published on 11/19/2026 at 02:41 | Editorial boerse-global.deBerenberg has raised its price target on Bayer from EUR 53.50 to EUR 62.00 while keeping its rating at "Hold" — a split verdict that captures the tension running through the investment case after a 51% share-price gain since the start of the year. The private bank's move, dated to yesterday, came as the stock slipped 0.5%.
At the heart of the positive case is a forecast that outpaces the wider market: Berenberg expects Bayer's pharmaceuticals division to generate EUR 5 billion in EBITDA in 2027, against a consensus of EUR 4.8 billion. Analyst Sebastian Bray credits the strong equity performance and points to a possible Monsanto listing before the end of the decade, with proceeds potentially channelled into drug development. He stops short, however, of turning that into a buy recommendation — improved earnings expectations and a cautious stance, in his view, are not mutually exclusive.
Nubeqa and Kerendia Carry the Optimistic Case
The bullish scenario rests on the two growth drivers Berenberg names: Nubeqa and Kerendia. Should they develop in line with the more optimistic reading, the pharma division could underpin the higher earnings forecast — and, for the shares, the key question is whether that translates into a durably firmer earnings path. If the business merely tracks existing market expectations, Berenberg's extra optimism would remain unfulfilled.
UBS shares the operational reference point but not the conclusion on valuation. On 4 November the house reiterated its buy rating and lifted its target to EUR 66, with analyst Matthew Weston citing strong quarterly results and, in particular, the continued pharmaceuticals division.
Should investors sell immediately? Or is it worth buying Bayer?
Guidance Raised, Quarterly Loss Narrowed
Bayer lifted its full-year outlook in early November, raising targets for the Pharmaceuticals margin, group EBITDA before special items and free cash flow. Third-quarter revenue climbed to EUR 10.05 billion from EUR 9.66 billion a year earlier, while EBITDA before special items rose to EUR 1.62 billion. Earnings per share improved to -EUR 0.69 from -EUR 0.98 — a narrower loss, though still negative for the quarter.
That group-level figure cannot be measured directly against the divisional EBITDA forecast; the two illuminate different layers of the business. Treating the optimistic segment estimate as proof of a broadly secured earnings trajectory for the whole company would therefore fall short.
Sunharbo Adds a Regulatory Catalyst
November also brought a regulatory milestone. The US Food and Drug Administration approved Asundexian under the brand name Sunharbo — which Bayer describes as the world's first approved factor XIa inhibitor. The clearance covers certain adults after a non-cardioembolic ischemic stroke or a high-risk TIA, where Sunharbo is intended to lower stroke risk and is combined with antiplatelet therapy. The FDA assessed efficacy in the Phase III OCEANIC-STROKE trial, which enrolled 12,327 adults. Bayer expected shipping to begin in mid-to-late November.
Bayer at a turning point? This analysis reveals what investors need to know now.
The Next Test Arrives in February
The gap between operational improvement and already-elevated expectations remains the serious counterargument. Even a fundamentally solid performance could prove insufficient to generate fresh upside after such a strong year, particularly if pharma growth continues but lags the bullish analyst view. Should expectations for the earnings contribution of Nubeqa and Kerendia falter, the rationale for a higher valuation loses weight too.
The next concrete checkpoint is the fourth-quarter 2026 report, expected on 24 February 2027. What matters then is evidence that Bayer can back the higher pharma expectations operationally. The benchmark for investors is set: not a repeat of the share-price recovery, but a more robust earnings improvement — only then can the pharma business be judged more convincingly as deserving of further revaluation.
Ad
Bayer Stock: New Analysis - 19 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
